Sutro Biopharma Short Term Debt Over Time
| STRO Stock | USD 2.60 0.01 0.38% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Sutro Biopharma Performance and Sutro Biopharma Correlation. Sutro |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Revenue Per Share 2.253 | Quarterly Revenue Growth (0.50) | Return On Assets (0.18) | Return On Equity (1.11) |
The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Short Term Debt Analysis
Compare Sutro Biopharma and related stocks such as Vaxcyte, Larimar Therapeutics, and Syndax Pharmaceuticals Short Term Debt Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PCVX | 297 K | 297 K | 297 K | 297 K | 297 K | 297 K | 297 K | 297 K | 297 K | 161 K | 10.6 M | 10.6 M | 11.8 M | 14.2 M | 8.2 M |
| LRMR | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 2.9 M | 3.6 M | 5.5 M | 5.5 M | 97 K | 1 M | 1.2 M | 1.2 M | 837 K | 1.6 M |
| SNDX | 21.3 M | 21.3 M | 21.3 M | 6.4 M | 6.4 M | 1.9 M | 6.4 M | 11.8 M | 13 M | 478 K | 2.6 M | 362 K | 439 K | 1 M | 994.6 K |
| MRUS | 225.2 K | 225.2 K | 225.2 K | 230.6 K | 203.1 K | 182.6 K | 175.6 K | 9.8 M | 292.8 K | 1.4 M | 1.4 M | 1.5 M | 1.7 M | (28.4 M) | (27 M) |
| IDYA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 M | 3.1 M | 3.4 M | 3.7 M | 3.5 M | 2.3 M |
| ANAB | 932 K | 932 K | 932 K | 932 K | 129 K | 21 K | 1000 | 6.9 M | 7.6 M | 2.2 M | 342 K | 3 M | 3.3 M | 3.6 M | 2.8 M |
| MGTX | 6 K | 6 K | 6 K | 6 K | 6 K | 6 K | 6 K | 1.5 M | 27.2 K | 1.7 M | 2.6 M | 6.7 M | 7.8 M | 4.2 M | 3.4 M |
| KROS | 166 K | 166 K | 166 K | 166 K | 166 K | 166 K | 166 K | 166 K | 166 K | 376 K | 846 K | 1.7 M | 910 K | 1 M | 921.6 K |
| NAMSW | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 60 K | 66 K | 60 K | 57 K |
| CNTA | 544 K | 544 K | 544 K | 544 K | 544 K | 544 K | 544 K | 544 K | 544 K | 544 K | 5.6 M | 5.6 M | 5.6 M | 6.5 M | 3.4 M |
| OPT | 5.9 K | 69.1 K | 69.1 K | 69.1 K | 69.1 K | 69.1 K | 69.1 K | 69.1 K | 69.1 K | 69.1 K | 113 K | 97.5 K | 97.5 K | 93 K | 88.4 K |
| HLVX | 906 K | 906 K | 906 K | 906 K | 906 K | 906 K | 906 K | 906 K | 906 K | 906 K | 3 M | 158.3 M | 74 K | 6.2 M | 5.9 M |
| AVTE | 384 K | 384 K | 384 K | 384 K | 384 K | 384 K | 384 K | 384 K | 384 K | 384 K | 384 K | 384 K | 770 K | 840 K | 731.1 K |
| MLYS | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4 M | 3.6 M |
| REPL | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 6.9 M | 7.3 M | 3.8 M | 7.8 M | 6.4 M |
Sutro Biopharma and related stocks such as Vaxcyte, Larimar Therapeutics, and Syndax Pharmaceuticals Short Term Debt description
My Equities
My Current Equities and Potential Positions
| Sutro Biopharma | STRO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.6
Check out Sutro Biopharma Performance and Sutro Biopharma Correlation. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Sutro Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.